Cost-efficient HIV-1 drug resistance surveillance using multiplexed high-throughput amplicon sequencing: Implications for use in low- and middle-income countries

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 12, 2014, Pages 3349-3355

  Ekici, Halime ^a   Rao, Shwetha D ^b   Sönnerborg, Anders ^a   Ramprasad, Vedam L ^c   Gupta, Ravi ^c   Neogi, Ujjwal ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b ST JOHN'S NATIONAL ACADEMY OF HEALTH SCIENCES   (India)

^c SCIGENOM LABS PVT LTD   (India)

Author keywords

Genotypic resistance testing; Next generation sequencing; Primary drug resistance surveillance; Therapy naive

Indexed keywords

ADULT; AMPLICON; ARTICLE; CAUCASIAN; COST EFFECTIVENESS ANALYSIS; EAST AFRICAN; FEMALE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; INDIAN; LOW INCOME COUNTRY; MAJOR CLINICAL STUDY; MALE; MIDDLE INCOME COUNTRY; NEXT GENERATION SEQUENCING; PHYLOGENY; SEQUENCE ANALYSIS; SWEDEN; VIRUS MUTATION; VIRUS RESISTANCE; VIRUS TYPING; ANTIVIRAL RESISTANCE; COHORT ANALYSIS; DEVELOPING COUNTRY; EPIDEMIOLOGICAL MONITORING; EVALUATION STUDY; GENETICS; GENOTYPING TECHNIQUE; HIGH THROUGHPUT SEQUENCING; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDIA; ISOLATION AND PURIFICATION; MIDDLE AGED; PLASMA; PROCEDURES; VIROLOGY;

ADULT; COHORT STUDIES; DEVELOPING COUNTRIES; DRUG RESISTANCE, VIRAL; EPIDEMIOLOGICAL MONITORING; FEMALE; GENOTYPING TECHNIQUES; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HIV INFECTIONS; HIV-1; HUMANS; INDIA; MALE; MIDDLE AGED; PLASMA;

EID: 84937239157     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku278     Document Type: Article

References (31)

1. Gilks CF, Crowley S, Ekpini R et al. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 2006; 368: 505-10.
2. WHO, UNAIDS, UNICEF. Towards Universal Access: Scaling up Priority HIV/AIDS Interventions in the Health Sector. Progress Report 2008. Geneva, Switzerland: WHO, 2008. http://www.who.int/hiv/pub/towards_universal_access_report_2008.pdf (13 March 2014, date last accessed).
3. Hamers RL, Sigaloff KC, Kityo C et al. Emerging HIV-1 drug resistance after roll-out of antiretroviral therapy in sub-Saharan Africa. Curr Opin HIV AIDS 2013; 8: 19-26.
4. Gupta RK, Jordan MR, Sultan BJ et al. Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis. Lancet 2012; 380: 1250-8.
5. Price MA,Wallis CL, Lakhi S et al. Transmitted HIV type 1 drug resistance among individuals with recent HIV infection in East and Southern Africa. AIDS Res Hum Retroviruses 2011; 27: 5-12.
6. Neogi U, Gupta S, Palchaudhuri R et al. Limited evolution but increasing trends of primary non-nucleoside reverse transcriptase inhibitor resistance mutations in therapy-naive HIV-1-infected individuals in India. Antivir Ther 2014; doi:10.3851/IMP2769.
7. Rahim S, Fredrick LM, da Silva BA et al. Geographic and temporal trends of transmitted HIV-1 drug resistance among antiretroviral-naive subjects screening for two clinical trials in North America and Western Europe. HIV Clin Trials 2009; 10: 94-103.
8. Bontell I, Haggblom A, Bratt G et al. Trends in antiretroviral therapy and prevalence of HIV drug resistance mutations in Sweden 1997-2011. PLoS One 2013; 8: e59337.
9. Vercauteren J, Wensing AM, van de Vijver DA et al. Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis 2009; 200: 1503-8.
10. Li JZ, Paredes R, Ribaudo HJ et al. Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. JAMA 2011; 305: 1327-35.
11. Li X, Buckton AJ, Wilkinson SL et al. Towards clinical molecular diagnosis of inherited cardiac conditions: a comparison of bench-top genome DNA sequencers. PLoS One 2013; 8: e67744.
12. Loman NJ, Misra RV, Dallman TJ et al. Performance comparison of benchtop high-throughput sequencing platforms. Nat Biotechnol 2012; 30: 434-9.
13. Junemann S, Sedlazeck FJ, Prior K et al. Updating benchtop sequencing performance comparison. Nat Biotechnol 2013; 31: 294-6.
14. Neogi U, Sahoo PN, De Costa A et al. High viremia and lowlevel of transmitted drug resistance in anti-retroviral therapy-naive perinatally-infected children and adolescents with HIV-1 subtype C infection. BMC Infect Dis 2012; 12: 317.
15. Woods CK, Brumme CJ, Liu TF et al. Automating HIV drug resistance genotyping with RECall, a freely accessible sequence analysis tool. J Clin Microbiol 2012; 50: 1936-42.
16. Guindon S, Dufayard JF, Lefort V et al. New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0. Syst Biol 2010; 59: 307-21.
17. Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet.journal 2011; 17: 10-2.
18. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Methods 2012; 9: 357-9.
19. Li H, Handsaker B, Wysoker A et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 2009; 25: 2078-9.
20. Bennett DE, Camacho RJ, Otelea D et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One 2009; 4: e4724.
21. Simen BB, Simons JF, Hullsiek KH et al. Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes. J Infect Dis 2009; 199: 693-701.
22. Mohamed S, Ravet S, Camus C et al. Clinical and analytical relevance of NNRTIs minority mutations on viral failure in HIV-1 infected patients. J Med Virol 2014; 86: 394-403.
23. Palmer S, Kearney M, Maldarelli F et al. Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatmentexperienced patients are missed by standard genotype analysis. J Clin Microbiol 2005; 43: 406-13.
24. Halvas EK, Aldrovandi GM, Balfe P et al. Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency. J Clin Microbiol 2006; 44: 2612-4.
25. Le T, Chiarella J, Simen BB et al. Low-abundance HIV drug-resistant viral variants in treatment-experienced persons correlate with historical antiretroviral use. PLoS One 2009; 4: e6079.
26. Fisher R, van Zyl GU, Travers SA et al. Deep sequencing reveals minor protease resistance mutations in patients failing a protease inhibitor regimen. J Virol 2012; 86: 6231-7.
27. Lander ES,Waterman MS. Genomic mapping by fingerprinting random clones: a mathematical analysis. Genomics 1988; 2: 231-9.
28. Dudley DM, Chin EN, Bimber BN et al. Low-cost ultra-wide genotyping using Roche/454 pyrosequencing for surveillance of HIV drug resistance. PLoS One 2012; 7: e36494.
29. Ji H, Liang B, Li Yet al. Lowabundance drug resistance variants in transmitted HIV drug resistance surveillance specimens identified using tagged pooled pyrosequencing. J Virol Methods 2013; 187: 314-20.
30. Ji H, Li Y, Graham M et al. Next-generation sequencing of dried blood spot specimens: a novel approach to HIV drug-resistance surveillance. Antivir Ther 2011; 16: 871-8.
31. Lange V, Bohme I, Hofmann J et al. Cost-efficient high-throughput HLA typing by MiSeq amplicon sequencing. BMC Genomics 2014; 15: 63.